Acorda Therapeutics Total Assets 2006-2021 | ACOR

Acorda Therapeutics total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Acorda Therapeutics Annual Total Assets
(Millions of US $)
2020 $633
2019 $800
2018 $1,300
2017 $1,198
2016 $1,342
2015 $1,111
2014 $1,065
2013 $607
2012 $565
2011 $379
2010 $342
2009 $319
2008 $282
2007 $127
2006 $84
2005 $34
Acorda Therapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $466
2021-06-30 $491
2021-03-31 $584
2020-12-31 $633
2020-09-30 $710
2020-06-30 $728
2020-03-31 $754
2019-12-31 $800
2019-09-30 $880
2019-06-30 $1,197
2019-03-31 $1,234
2018-12-31 $1,300
2018-09-30 $1,311
2018-06-30 $1,251
2018-03-31 $1,187
2017-12-31 $1,198
2017-09-30 $1,345
2017-06-30 $1,332
2017-03-31 $1,320
2016-12-31 $1,342
2016-09-30 $1,318
2016-06-30 $1,347
2016-03-31 $1,212
2015-12-31 $1,111
2015-09-30 $1,100
2015-06-30 $1,101
2015-03-31 $1,099
2014-12-31 $1,065
2014-09-30 $973
2014-06-30 $943
2014-03-31 $612
2013-12-31 $607
2013-09-30 $587
2013-06-30 $576
2013-03-31 $565
2012-12-31 $565
2012-09-30 $410
2012-06-30 $403
2012-03-31 $386
2011-12-31 $379
2011-09-30 $351
2011-06-30 $336
2011-03-31 $336
2010-12-31 $342
2010-09-30 $331
2010-06-30 $296
2010-03-31 $318
2009-12-31 $319
2009-09-30 $338
2009-06-30 $368
2009-03-31 $262
2008-12-31 $282
2008-09-30 $298
2008-06-30 $184
2008-03-31 $196
2007-12-31 $127
2007-09-30 $137
2007-06-30 $134
2007-03-31 $68
2006-12-31 $84
2006-09-30 $40
2006-06-30 $44
2006-03-31 $50
2005-12-31 $34
2005-09-30 $0
2005-06-30 $0
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69